BDTX240920P5000
- 0.75
- -0.10-11.76%
Black Diamond Therapeutics Newsroom
Buy Rating Affirmed for Black Diamond Therapeutics Amid Promising NSCLC Treatment Advances
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients With Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
Daily futures tracking | Chip stocks have rebounded over the past few days, Nvidia and Broadcom single trading are active; gold and silver spot has soared, and related ETF bullish options have earned nearly 20 times overnight
Are bears sniping at Intel? The bearish ratio rose to 72%, and put trading volume increased dramatically; Broadcom rose by 3.97% to lead the rise in star technology stocks, and earned 6 times the profit from a single call due in October.
Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $15
Stifel analyst Bradley Canino maintains $Black Diamond Therapeutics(BDTX.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 41.
Wedbush Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $16
Wedbush analyst Robert Driscoll maintains $Black Diamond Therapeutics(BDTX.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 4
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $12
Piper Sandler analyst Joseph Catanzaro maintains $Black Diamond Therapeutics(BDTX.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success
Black Diamond Therapeutics (BDTX) Gets a Buy From Piper Sandler
HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $11
H.C. Wainwright analyst Robert Burns maintains $Black Diamond Therapeutics(BDTX.US)$ with a buy rating, and maintains the target price at $11.According to TipRanks data, the analyst has a success
Looking Into Black Diamond Therapeutic's Recent Short Interest
Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM
Daily options tracking: Investors buying technology stocks on dips! Options of Nvidia and Tesla are popular; Starbucks's change of leadership leads to a surge in stock price, with one call option profiting 789 times.
Tesla rebounded more than 5% overnight. The options for calls increased for many consecutive days, reaching 63.3%. The most active transactions on the options chain are calls for exercising at 210/205 dollars which expire on Friday. Two large orders both achieved a doubling increase, rising by 200%.
Catalyst Watch: Eyes on Walmart Earnings, the July CPI Print, and 13F Filings
Institutional Owners May Ignore Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Recent US$67m Market Cap Decline as Longer-term Profits Stay in the Green
Express News | Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.d., to Board of Directors
Black Diamond Theraptcs Price Target Maintained With a $16.00/Share by Wedbush
Wedbush Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating
TD Cowen analyst Marc Frahm maintains $Black Diamond Therapeutics(BDTX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.8% and a total average return of 17.7%
Buy Rating on Black Diamond Therapeutics: Promising Early Results for BDTX-1535 in NSCLC Treatment
Earnings Flash (BDTX) BLACK DIAMOND THERAPEUTICS Posts Q2 Loss $-0.36 Per Share